• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

7.480 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 8,710
Open 7.480
Bid (Size) 7.440 (1,100)
Ask (Size) 7.480 (300)
Prev. Close 7.480
Today's Range 7.480 - 7.480
52wk Range 1.830 - 12.43
Shares Outstanding 391,156,513
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX
April 09, 2026
From SkyMedia, LLC
Via GlobeNewswire
News headline image
ImmunityBio (IBRX): From R&D Speculation to Record Commercial Revenue
April 09, 2026
Today's Date: April 9, 2026 Introduction In the high-stakes arena of biotechnology, few companies have undergone a transformation as dramatic as ImmunityBio, Inc. (NASDAQ: IBRX). Long viewed by Wall... 
Via Finterra
Topics Economy World Trade

Performance

YTD
+270.3%
+270.3%
1 Month
-6.6%
-6.6%
3 Month
+233.9%
+233.9%
6 Month
+206.6%
+206.6%
1 Year
+187.7%
+187.7%

More News

Read More
News headline image
Kaplan Fox Encourages Investors of ImmunityBio, Inc. (NASDAQ: IBRX) to Contact the Firm Before Lead Plaintiff Deadline on May 26, 2026
April 09, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
Kaplan Fox Encourages Investors of ImmunityBio, Inc. (NASDAQ: IBRX) to Contact the Firm Before Lead Plaintiff Deadline on May 26, 2026
April 09, 2026
Via TheNewswire.com
Topics Lawsuit
News headline image
IMMUNITYBIO, INC. (IBRX) DEADLINE ALERT Bernstein Liebhard LLP Reminds ImmunityBio, Inc. Investors of Upcoming Deadline
April 09, 2026
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
April 08, 2026
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ImmunityBio, Inc. (IBRX) Class Action Lawsuit Seeks Recovery for Investors; May 26, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP
April 08, 2026
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Kaplan Fox Alerts Investors of ImmunityBio, Inc. (IBRX) to a Securities Class Action Deadline on May 26, 2026
April 08, 2026
Via NewMediaWire
Topics Lawsuit
News headline image
Kaplan Fox Alerts Investors of ImmunityBio, Inc. (IBRX) to a Securities Class Action Deadline on May 26, 2026
April 08, 2026
Via TheNewswire.com
Topics Lawsuit
News headline image
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
April 07, 2026
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines – IBRX
April 07, 2026
From Pomerantz LLP
Via GlobeNewswire
News headline image
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misbranded Cancer Drug: Levi & Korsinsky
April 07, 2026
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
April 07, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 07, 2026
From Schall Law
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX)
April 07, 2026
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Why ImmunityBio Stock Slumped on Monday ↗
April 06, 2026
Via The Motley Fool
News headline image
ImmunityBio, Inc. (IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit
April 06, 2026
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ImmunityBio, Inc. (IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit
April 06, 2026
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance
April 06, 2026
From ImmunityBio, Inc.
Via Business Wire
News headline image
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit
April 05, 2026
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit
April 05, 2026
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX
April 04, 2026
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff Deadline
April 04, 2026
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
ImmunityBio, Inc. (IBRX) Securities Fraud Class Action Lawsuit Filed; May 26, 2026, Lead Plaintiff Deadline
April 04, 2026
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
April 03, 2026
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire

Frequently Asked Questions

Is ImmunityBio, Inc. - Common Stock publicly traded?
Yes, ImmunityBio, Inc. - Common Stock is publicly traded.
What exchange does ImmunityBio, Inc. - Common Stock trade on?
ImmunityBio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ImmunityBio, Inc. - Common Stock?
The ticker symbol for ImmunityBio, Inc. - Common Stock is IBRX on the Nasdaq Stock Market
What is the current price of ImmunityBio, Inc. - Common Stock?
The current price of ImmunityBio, Inc. - Common Stock is 7.480
When was ImmunityBio, Inc. - Common Stock last traded?
The last trade of ImmunityBio, Inc. - Common Stock was at 04/09/26 04:00 PM ET
What is the market capitalization of ImmunityBio, Inc. - Common Stock?
The market capitalization of ImmunityBio, Inc. - Common Stock is 2.93B
How many shares of ImmunityBio, Inc. - Common Stock are outstanding?
ImmunityBio, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap